More than 2.5 million eye drops are recalled in the United States due to contamination

Millions of bottles of an eye medication often used to treat allergies and inflammation have been recalled nationwide, the U.S. Food and Drug Administration (FDA) announced last week. The statement highlights the scope of the measure that affects consumers in several regions.
The reason for the withdrawal of prednisolone acetate eye drops from the market is the possible presence of a foreign substance in its composition, information confirmed in the official recall notice. This detection motivated preventive action.
Lupine Pharmaceuticals Inc., responsible for manufacturing the medicine sold under medical prescription, is voluntarily recalling more than 2.5 million bottles of the product across the country.
Prednisolone is a potent corticosteroid, used to alleviate symptoms such as redness, itching and swelling in cases of eye infections and other conditions. It is crucial to highlight that access to this medicine requires a prescription.

Important details about affected vials
To help identify the products involved, the FDA released the following information:
- Product Description: Prednisolone Acetate Ophthalmic Suspension, USP, 1%, for prescription use only.
- Presentations: 5 mL (NDC 70748-332-02), 10 mL (NDC 70748-332-03) and 15 mL (NDC 70748-332-04).
- Place of manufacture: Lupine Limited, Pithampur (MP) 454 775, India.
- Total volume: 2,530,182 bottles.
- Recall number: D-0655-2026.
The recall process began at the beginning of last month, but was officially classified as “Class II” by the FDA last week, covering dozens of different batches. To find out if your prescription has been affected, it is advisable to consult a healthcare professional or the manufacturer.
A Class II classification by the FDA indicates that use or exposure to the product may lead to adverse health consequences that are temporary or medically reversible. This designation points to a significant risk, even if it is not immediately fatal.
Lupine Pharmaceuticals Inc. was contacted for comment on the case, but there was no immediate response from the company at the time of publishing this article.






